Rybelsus: an oral formulation of the GLP‐1 agonist semaglutide
Sign Up to like & getrecommendations! Published in 2020 at "Prescriber"
DOI: 10.1002/psb.1873
Abstract: Rybelsus (semaglutide) is the first GLP‐1 agonist for the treatment of type 2 diabetes to be available as an oral formulation. This article discusses its properties, efficacy and adverse effects. read more here.
Keywords: rybelsus oral; agonist semaglutide; formulation glp; glp agonist ... See more keywords